Allergy Therapeutics PLC Director Dealings (0193S)
11 November 2021 - 6:00PM
UK Regulatory
TIDMAGY
RNS Number : 0193S
Allergy Therapeutics PLC
11 November 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director Dealings
11 November 2021 - Allergy Therapeutics (AIM: AGY), the fully
integrated specialty pharmaceutical group specialising in allergy
vaccines, announces that Peter Jensen, Non-Executive Chairman, has
purchased 30,000 ordinary shares of 0.1 pence each in the capital
of the Company ("Ordinary Shares") at a price of 36 pence per
Ordinary Share. Following the transaction, the total beneficial
interest of Peter Jensen is 300,000 Ordinary Shares, representing
0.05% of the of the issued share capital of the Company to which
voting rights are attached.
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott, David Daley, Davide Salvi, Alex Gunter
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m2 of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved 10% compound annual
growth since formation, employs c.500 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Jensen
------------------------------------------------------------ ------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------
Non-Executive Chairman, Director
a) Position/status
------------------------------------------------------------ ------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ ------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------------------
a) Name Allergy Therapeutics plc
------------------------------------------------------------ ------------------------------------
b) LEI 213800PQ7AHK7KGVOE23
------------------------------------------------------------ ------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument 0.1p ordinary shares
Identification code
GB00B02LCQ05
------------------------------------------------------------ ------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------------------------ ------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Volume(s)
Share
36 pence 30,000
------------------------------------------------------------ ------------------------------------
d) Aggregated information
N/A
------------------------------------------------------------ ------------------------------------
e) Date of the transaction 1 0 November 2021
------------------------------------------------------------ ------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------ ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMZMMMMGZGMZZ
(END) Dow Jones Newswires
November 11, 2021 02:00 ET (07:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
